-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on AtriCure, Raises Price Target to $60

Benzinga·08/27/2026 16:43:01
语音播报
Piper Sandler analyst Matt O'Brien maintains AtriCure (NASDAQ:ATRC) with a Overweight and raises the price target from $50 to $60.